NDAORALSOLUTION
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion…
Indications (16)
hypertensionto lower blood pressure in adultsClinical Studies ( )]symptomatic heart failureusually in combination with diureticsdigitalisheart failureof high blood pressure should be part of comprehensive cardiovascular risk managementincludingappropriatelipid controldiabetes managementantithrombotic therapysmoking cessationexerciselimited sodium intake
Loss of Exclusivity
LOE Date
Mar 25, 2036
122 months away
Patent Expiry
Mar 25, 2036
Company
R-Pharm US
NJ - Princeton